Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic.
Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic.
复制标题
DOI：
10.1615/critrevtherdrugcarriersyst.v26.i6.10
复制
发表时间：
2009
影响因子：
2.7
通讯作者：
Blumenthal R
中科院分区：
文献类型：
--
作者：
Puri A;Loomis K;Smith B;Lee JH;Yavlovich A;Heldman E;Blumenthal R
近年来，医学生物学领域的各种纳米技术平台，包括诊断和治疗方面，都受到了极大的关注。此外，在过去十年中，作为药物载体的工程化多功能纳米粒子的研发促使其在医学应用方面呈指数增长。这些纳米粒子的设计原理，包括纳米乳剂、树枝状大分子、纳米金、脂质体、药物 - 载体偶联物、抗体 - 药物复合物和磁性纳米粒子等，主要基于合成、天然或生物成分的独特组合，包括但不限于合成聚合物、金属离子、油和脂质作为其构建模块。然而，这些粒子在临床上能否取得潜在成功取决于对一些重要参数的考虑，例如纳米粒子的制备策略、其物理性质、载药效率、药物释放潜力，以及最重要的是载体本身的最小毒性。其中，基于脂质的纳米粒子在体内应用中具有毒性最小的优势，并且在使用基于脂质的纳米组装体进行DNA/RNA和药物递送方面已经取得了重大进展。在这篇综述中，我们将主要关注基于脂质的纳米粒子在药物递送方面的预期应用的最新进展和动态。我们首先回顾脂质体（所谓的荣誉纳米粒子）领域的当前研究活动，并将详细讨论靶向和触发等具有挑战性的问题。我们还将进一步描述由一类新型的两亲性脂质（称为bolaamphiphiles）衍生的纳米粒子，这类脂质具有独特的脂质组装特征，最近已被作为药物/DNA递送载体进行研究。最后，将对一类新兴的新型粒子（基于除磷脂以外的脂质成分），即固体脂质纳米粒子和纳米结构脂质载体进行概述。我们将以目前临床上成功的几种基于脂质的纳米粒子制剂为例进行总结。
In recent years, various nanotechnology platforms in the area of medical biology, including both diagnostics and therapy, have gained remarkable attention. Moreover, research and development of engineered multifunctional nanoparticles as pharmaceutical drug carriers have spurred exponential growth in applications to medicine in the last decade. Design principles of these nanoparticles, including nano-emulsions, dendrimers, nano-gold, liposomes, drug-carrier conjugates, antibody-drug complexes, and magnetic nanoparticles, are primarily based on unique assemblies of synthetic, natural, or biological components, including but not limited to synthetic polymers, metal ions, oils, and lipids as their building blocks. However, the potential success of these particles in the clinic relies on consideration of important parameters such as nanoparticle fabrication strategies, their physical properties, drug loading efficiencies, drug release potential, and, most importantly, minimum toxicity of the carrier itself. Among these, lipid-based nanoparticles bear the advantage of being the least toxic for in vivo applications, and significant progress has been made in the area of DNA/RNA and drug delivery using lipid-based nanoassemblies. In this review, we will primarily focus on the recent advances and updates on lipid-based nanoparticles for their projected applications in drug delivery. We begin with a review of current activities in the field of liposomes (the so-called honorary nanoparticles), and challenging issues of targeting and triggering will be discussed in detail. We will further describe nanoparticles derived from a novel class of amphipathic lipids called bolaamphiphiles with unique lipid assembly features that have been recently examined as drug/DNA delivery vehicles. Finally, an overview of an emerging novel class of particles (based on lipid components other than phospholipids), solid lipid nanoparticles and nanostructured lipid carriers will be presented. We conclude with a few examples of clinically successful formulations of currently available lipid-based nanoparticles.
登录
查看更多内容
影响因子：
3.4
作者：
AGARWAL, K;BALI, A;GUPTA, CM
通讯作者：
GUPTA, CM
影响因子：
2
作者：
Atobe, Kazutaka;Ishida, Tatsuhiro;Kiwada, Hiroshi
通讯作者：
Kiwada, Hiroshi
影响因子：
7.5
作者：
Alonso, MJ
通讯作者：
Alonso, MJ
影响因子：
4
作者：
Arakawa, K;Eguchi, T;Kakinuma, K
通讯作者：
Kakinuma, K
影响因子：
50.5
作者：
Andreopoulou, E.;Gaiotti, D.;Muggia, F.
通讯作者：
Muggia, F.